Navigation Links
AtriCure Reports First Quarter 2008 Financial Results
Date:5/6/2008

e of AtriCure's products, AtriCure's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure's products, competition from existing and new products and procedures or AtriCure's ability to effectively react to other risks and uncertainties described from time to time in AtriCure's SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation (including the purported class action lawsuit) or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:

AtriCure, Inc.

Julie A. Piton

Vice President and Chief Financial Officer

(513) 755-4561

jpiton@atricure.com

ATRICURE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended March 31,

2008 2007

Revenues $13,530,145 $10,750,770

Cost of revenues 3,230,880 2,210,495

Gross profit 10,299,265 8,540,275

Operating expenses:

Research and development expenses 2,433,154 3,129,278

Selling, general and

administrative expenses 11,762,426 10,283,187

Total operating
'/>"/>

SOURCE AtriCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
2. Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
3. Vion Reports 2008 First Quarter Results
4. eResearchTechnology Reports First Quarter 2008 Results
5. MannKind Corporation Reports First Quarter Financial Results
6. Verenium Reports Financial Results for the First Quarter 2008
7. ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
8. United Therapeutics Reports First Quarter 2008 Financial Results
9. Endocare Reports 2008 First Quarter Financial Results
10. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
11. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Earlier this year in a June 24 ... Adult Stem Cell Technology Center, LLC ( ASCTC ) focused ... of adult tissue stem cells. His title “Asymmetric Self-Renewal ... the Future,” embodied the essence of his message to congress ...
(Date:12/24/2014)... On Friday, December 19, 2014, President Obama signed ... Appropriations Act of 2015, which for the first time, ... the Congressionally Directed Medical Research Programs (CDMRP) administered by ... working in conjunction with its allies on Capitol Hill, ...
(Date:12/24/2014)... 23, 2014 The report provides ... definition, classification, application and industry overview. This report ... cost structure. Production is separated by regions, technology ... materials, equipment, downstream client survey, marketing channels, industry ...
(Date:12/24/2014)... 24, 2014 The report expects global cell ... It also provides a carefully analyzed data about the vital ... , Full Copy of Report @ http://bit.ly/1yUxy0T , ... will keep witnessing growth at an impressive CAGR during near ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... ... Coverage, ... biopharmaceutical company focusing on the development of,novel, proprietary antibody-based products for ... developed,using BiTE(R) technology will be reported at the joint international,meeting of ...
... N.C., Oct. 23 Coordinating and timing,activities is ... the results of clinical trials. Marketers, who have ... trials,need to "worry about competitors stealing your thunder, ... was about," states one,interviewed executive. According to ...
... 22, 2007 In a major feat of nanotechnology ... with a wide-range of potential applications in chemistry, biology ... the device is capable of resolving the chemical composition ... with unprecedented detail. , Spearheaded by graduate students Nanfang ...
Cached Biology Technology:Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference 2Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference 3Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference 4Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference 5Communicating Clinical Trial Data: Timing Remains Key Challenge for Marketing Teams 2Harvard University engineers demonstrate quantum cascade laser nanoantenna 2
(Date:1/22/2015)... 16, 2015  A man-made form of insulin delivered by ... capabilities in adults with mild cognitive impairment and Alzheimer,s ... researchers at Wake Forest Baptist Medical Center. ... mild cognitive impairment (MCI) or mild to moderate Alzheimer,s ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/fx4bg3/the_global ) has ... Watermarking and Fingerprinting Markets" report to their ... This insight provides an overview of ... Watermarking aims to control and monitor piracy by ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2
... ID Technology Now Embedded in a Fully Flexible ... ... Dec. 5 Fidelica Microsystems, Inc., a,pioneering developer of ... company,s FSC-3012 Biometrically,Authenticated Smart Card. This biometrically-authenticated credential,features a ...
... prices rise, the costs of lower-calorie foods are rising the ... the December issue of the Journal of the American Dietetic ... other low-calorie foods have jumped nearly 20 percent in the ... may be moving out of the reach of some American ...
... so that they will rethink how an object works ... using that object, according to a Yale study today ... Even when you add time pressure, or warn the ... unable to avoid reproducing the adults irrelevant actions, said ...
Cached Biology News:Fidelica Microsystems Announces Biometrically-Authenticated Smart Card 2Price of lower-calorie foods rising drastically, researchers find 2Humans appear hardwired to learn by 'over-imitation' 2
... anti-phospho-FAK (Ser843) ... acid region encompassing the human, mouse, ... Accession Number: NM_153831 ... Routinely evaluated by immunoblot. ...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Phospho-YAP (Ser127) Antibody Ship: Hot Store: -20 C...
Biology Products: